Eli Lilly Goes 'Graves Robbing' With a $2.88B Merida Biosciences Buyout (Novo Be Seething)

By Stocks News   |   2 months ago   |   Stock Market News
Eli Lilly Goes 'Graves Robbing' With a $2.88B Merida Biosciences Buyout (Novo Be Seething)

“Let the antibodies hit the floor… “ - Drowning Pool Eli Lilly 

Another Monday, another biotech disappearing into Eli Lilly's abyss. The trillion-dollar Weight Watchers executioner agreed to buy Merida Biosciences for up to $2.88 billion in cash, pushing its 2026 shopping addiction business development program to roughly ten companies and north of $25 billion. 

“Merida Biosciences?” - you, probably… 

Yes, the Cambridge biotech that crawled out of stealth in April 2025 with $121 million from Bain Capital, Third Rock, BVF, and friends. Sixteen months and exactly one Phase 1 trial later, Lilly backed up the Brinks truck to the tune of 23x that raise, which, must be nice. 

The reason for the splurge is because Merida's lead drug, MER511, goes after Graves' disease (think: your thyroid gets stuck in overdrive and floods the body with hormone) and thyroid eye disease. Today's treatment menu is bleak as it includes drugs that dial down your entire immune system, radioactive iodine, or surgery. MER511 instead hunts down only the specific antibodies causing the problem and leaves the rest of your immune system alone. Early data says it works: antibody levels down big, no scary safety flags yet.

That said, the interesting thing is that MER511 isn't the whole haul. Lilly also gets MER769, an experimental shot at food allergies and asthma, plus earlier programs in kidney and other immune conditions… a genuinely girthy pipeline of new products. Per Lilly immunology boss Francisco Ramírez-Valle, the goal is "therapies that meaningfully change the course of disease, not just its downstream effects." Sounds legit. 

As for the competition in this market, thyroid eye disease currently has exactly two FDA-approved drugs, Amgen's Tepezza and Viridian's Lumvoa, and those two spent the summer slap-fighting over infusion schedules. Meaning, the prize for winning that fight is a trillion-dollar rival now lining up to "penetrate" their market. Sucks to suck, fellas.

Friendly reminder, Lilly can afford all of this because the GLP-1 money printer has been stuck on brrr for two years now. Mounjaro did $9.9 billion last quarter, Zepbound chipped in another $4.9 billion, and in May Lilly became the first drugmaker to crack the cuatro comas club. Novo's big comeback swing, CagriSema, lost a head-to-head trial to Lilly's tirzepatide this summer, so Lilly now has Novo pinned in pretty much every position imaginable… CEO David Ricks told reports he was "pleased but not satisfied" after a 48% revenue quarter… which tracks, because satisfied people don't buy ten companies in eight months.

Regardless, if you’ve been looking for a read on Lilly, the playbook stands the same. Sell everyone and their mom on weight loss, then spend the winnings buying up every other disease before the fat skinny lady sings. Meanwhile, when do the enlargement pills roll out? Asking for a friend… 

Until next time! 

At the time of publishing, Stocks.News does not hold positions in companies mentioned in the article. 

 

Did you find this insightful?

Disclaimer: Information provided is for informational purposes only, not investment advice. We do not recommend buying or selling stocks. Stock price discussions are based on publicly available data. Readers should conduct their own research or consult a financial advisor before investing. Owners of this site have current positions in stocks mentioned throughout the site, Please Read Full Disclaimer for details Here https://app.stocks.news/page/disclaimer